August 24, 2021 – Eyenuk is proud to announce the expansion of our customer base in Germany for automated diabetic retinopathy (DR) detection by the EyeArt® artificial intelligence (AI) system. Now the EyeArt AI system…
July 28, 2021 – HealthCare Dynamics International (HCDI), a minority, woman-owned, small business specializing in health care quality improvement and transformation, recently implemented the EyeArt® artificial intelligence (AI) system for community-based diabetic eye screening in…
Eyenuk AI Technology Selected for Diabetic Eye Testing in Vietnam Supported by The Fred Hollows Foundation
LOS ANGELES, July 26, 2021 — Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, announced that its EyeArt® AI system for…
Eyenuk Announces $6.2 Million Financing to Accelerate Adoption of FDA-cleared AI Technology for Detection of Diabetic Retinopathy
Financing led by AXA IM’s Impact Investing strategy Los Angeles, CA, July 20, 2021 — Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI…
Calling all interested rural clinics in Virginia to join grant-supported diabetic eye screening program AT NO COST
Eyenuk’s clinical partner in Virginia has been awarded a government telemedicine grant to improve diabetic eye screening in rural Virginia. Clinical partners must be located in rural Virginia to be eligible, with preference given to…
The EyeArt® AI Eye Screening System is the most extensively validated AI technology for autonomous detection of diabetic retinopathy, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
* EyeArt® has US FDA clearance, CE marking as a class IIa medical device in the European Union, and a Health Canada license.
How can EyeArt Help?
The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit.
What does EyeArt Do?
The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects signs of disease, and returns an easy-to-read report in under 60 seconds.
How does EyeArt Work?
The EyeArt system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.
Why choose EyeArt?
The EyeArt system is the world’s most-validated artificial intelligence (AI) screening tool for diabetic retinopathy, demonstrating high real-world sensitivity and specificity. It is proven to be safe, fast, and consistent.
Exceptional Performance in Pivotal, Prospective, Multi-Center Clinical Trial
Dr. Jennifer I. Lim, MD, Marion H. Schenk Esq. Chair, Professor of Ophthalmology, and Director of Retina Service at the University of Illinois at Chicago presented the Eyenuk Clinical Trial study results at the ARVO 2019 Imaging in the Eye Conference in Vancouver, Canada. Dr. Lim spoke to MD Magazine about the study in a multi part interview series. Click on the video to watch the interview.